On Friday 20 September, the European Commission announced that it had extended the authorisation of the Imvanex vaccine to adolescents aged 12 to 17. It is the only vaccine against monkeypox currently authorised in the EU, together with an antiviral treatment (Tecovirimat SIGA).
The authorisation comes after the European Medicines Agency (EMA) deemed the vaccine effective and safe for this age group. Imvanex was first authorised in the EU in 2013 to protect adults against smallpox....